12,372 trials
Whole Cell Pertussis · Diphtheria · Hepatitis B
Primary: Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL — 39; 41; 37; 39 Participants
Severe Aortic Stenosis · Transcatheter Aortic Valve Replacement · Aortic Valve Replacement
Primary: Major Bleeding (BARC ≥3b) at 48 Hours or Before Hospital Discharge — 6.9; 9 percentage of participants — p=0.2692
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — -0.82; -0.39 score on a scale — p=<0.0001
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Grade 3 Symptoms (Solicited and Unsolicited) — 24; 3; 18; 3 Participants
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Grade 3 Adverse Events (AEs) (Solicited and Unsolicited) - Primary Period — 18; 10; 10; 12 Participants
Dry Eye Disease
Primary: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84 — 2.39; 2.40; -0.73; -0.71 units on a scale — p=0.6186
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84 — -0.07; 0.17 units on a scale — p=0.0007
Autistic Disorder
Primary: Clinical Global Impression-Improvement (CGI-I) — 3.1; 2.4 CGI- Improvement
Infections, Rotavirus
Primary: Number of Subjects With Any Rotavirus Gastroenteritis (RVGE) — 4; 3 Subjects — p=0.691
Chemotherapeutic Agent Toxicity · Neuropathy · Neurotoxicity Syndrome
Primary: Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of…
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 — -0.77; -0.44 Percent — p=0.035
Chronic Low Back Pain
Primary: Change in Average Pain Intensity Measured by the Change in Pain Intensity-Numeric Rating Scale (PI-NRS) Scores From Randomization Baseline to Week 12 of the Double-blind…
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — NA; 8.38 months — p=<0.0001
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) — -2.05; -1.19; -1.35 % of hemoglobin — p=<0.0001
Involutional Osteoporosis
Primary: Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry (DXA) at End of Study — 5.07; 3.36…